Related references
Note: Only part of the references are listed.Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function
Fredrick Van Goor et al.
JOURNAL OF CYSTIC FIBROSIS (2014)
Lung Clearance Index as an Outcome Measure for Clinical Trials in Young Children with Cystic Fibrosis A Pilot Study Using Inhaled Hypertonic Saline
Padmaja Subbarao et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis
Diana Bilton et al.
JOURNAL OF CYSTIC FIBROSIS (2013)
Adenoviral Gene Transfer Corrects the Ion Transport Defect in the Sinus Epithelia of a Porcine CF Model
Andrea E. Potash et al.
MOLECULAR THERAPY (2013)
Mechanism-based corrector combination restores ΔF508-CFTR folding and function
Tsukasa Okiyoneda et al.
NATURE CHEMICAL BIOLOGY (2013)
Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study
Antje Schuster et al.
THORAX (2013)
A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis
Eric W. F. W. Alton et al.
THORAX (2013)
Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection
J. P. Clancy et al.
THORAX (2013)
Assessment of F/HN-Pseudotyped Lentivirus as a Clinically Relevant Vector for Lung Gene Therapy
Uta Griesenbach et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2012)
Long-Term Inhaled Dry Powder Mannitol in Cystic Fibrosis An International Randomized Study
Moira L. Aitken et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2012)
Fosfomycin/Tobramycin for Inhalation in Patients with Cystic Fibrosis with Pseudomonas Airway Infection
Bruce C. Trapnell et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2012)
Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation
Patrick A. Flume et al.
CHEST (2012)
Novel Therapeutic Uses of Alpha-1 Antitrypsin: A Window to the Future
Adam Wanner et al.
COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2012)
Inhaled Hypertonic Saline in Infants and Children Younger Than 6 Years With Cystic Fibrosis The ISIS Randomized Controlled Trial
Margaret Rosenfeld et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Treatment of lung infection in patients with cystic fibrosis: Current and future strategies
Gerd Doering et al.
JOURNAL OF CYSTIC FIBROSIS (2012)
Ivacaftor potentiation of multiple CFTR channels with gating mutations
Haihui Yu et al.
JOURNAL OF CYSTIC FIBROSIS (2012)
Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung
Alejandro A. Pezzulo et al.
NATURE (2012)
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation
J. P. Clancy et al.
THORAX (2012)
Levofloxacin Inhalation Solution (MP-376) in Patients with Cystic Fibrosis with Pseudomonas aeruginosa
David E. Geller et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Pharmacokinetics and Safety of MP-376 (Levofloxacin Inhalation Solution) in Cystic Fibrosis Subjects
David E. Geller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis
M. Wilschanski et al.
EUROPEAN RESPIRATORY JOURNAL (2011)
Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study
D. Bilton et al.
EUROPEAN RESPIRATORY JOURNAL (2011)
Inhaled mannitol in patients with cystic fibrosis: A randomised open-label dose response trial
Alejandro Teper et al.
JOURNAL OF CYSTIC FIBROSIS (2011)
Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial
Michael W. Konstan et al.
JOURNAL OF CYSTIC FIBROSIS (2011)
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Bonnie W. Ramsey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Tobramycin Inhalation Powder for P. aeruginosa Infection in Cystic Fibrosis: The EVOLVE Trial
Michael W. Konstan et al.
PEDIATRIC PULMONOLOGY (2011)
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
Fredrick Van Goor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis
Michael D. Parkins et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2011)
Ataluren (PTC124) Induces Cystic Fibrosis Transmembrane Conductance Regulator Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis
Isabelle Sermet-Gaudelus et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
Performance of PARI eFlow®
Alan L. Coates
JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY (2010)
Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: a randomised trial
C. Minasian et al.
THORAX (2010)
The Impact of MRSA on Lung Function in Patients with Cystic Fibrosis
Gregory S. Sawicki et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2009)
Respiratory Microbiology of Patients With Cystic Fibrosis in the United States, 1995 to 2005
Samiya Razvi et al.
CHEST (2009)
Lung deposition of inhaled α1-proteinase inhibitor in cystic fibrosis and α1-antitrypsin deficiency
P. Brand et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
A Gamma Scintigraphy Study to Investigate Lung Deposition and Clearance of Inhaled Amikacin-Loaded Liposomes in Healthy Male Volunteers
Jeffry Weers et al.
JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY (2009)
Safety/Efficacy of Inhaled Human Alpha-1 Antitrypsin (AAT) in CF: A Phase II Clinical Study
E. Kerem et al.
Journal of Cystic Fibrosis (2009)
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
Fredrick Van Goor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Aerosol Antibiotics in Cystic Fibrosis
David E. Geller
RESPIRATORY CARE (2009)
Characterization of nebulized liposomal amikacin (Arikace™) as a function of droplet size
Zhili Li et al.
JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY (2008)
Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections
P. Meers et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Single-dose pharmacokinetics of aerosol MP-376 (levofloxacin solution for inhalation) in cystic fibrosis patients: PK-PD implications
P.C. Griffith et al.
Journal of Cystic Fibrosis (2008)
Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial
Eitan Kerem et al.
LANCET (2008)
The Impact of Incident Methicillin Resistant Staphylococcus Aureus Detection on Pulmonary Function in Cystic Fibrosis
Gregory S. Sawicki et al.
PEDIATRIC PULMONOLOGY (2008)
The science of aerosol delivery in cystic fibrosis
David E. Geller
PEDIATRIC PULMONOLOGY (2008)
PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model
Ming Du et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity
Antonella Caputo et al.
SCIENCE (2008)
Cystic fibrosis pulmonary guidelines - Chronic medications for maintenance of lung health
Patrick A. Flume et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
New pulmonary therapies for cystic fibrosis
Felix Ratjen
CURRENT OPINION IN PULMONARY MEDICINE (2007)
Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers
Samit Hirawat et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety
David E. Geller et al.
PEDIATRIC PULMONOLOGY (2007)
α1-antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients
M. Griese et al.
EUROPEAN RESPIRATORY JOURNAL (2007)
Gene therapy progress and prospects: cystic fibrosis
U. Griesenbach et al.
GENE THERAPY (2006)
Rescue of ΔF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules
F Van Goor et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2006)
Safety and efficacy of recombinant alpha1-antitrypsin therapy in cystic fibrosis
SL Martin et al.
PEDIATRIC PULMONOLOGY (2006)
Mucus clearance and lung function in cystic fibrosis with hypertonic saline
SH Donaldson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis
MR Elkins et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Microbiology of airway disease in a cohort of patients with Cystic Fibrosis
A Lambiase et al.
BMC INFECTIOUS DISEASES (2006)
Mechanisms of disease: Cystic fibrosis
SM Rowe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis
ZH Li et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis
J Emerson et al.
PEDIATRIC PULMONOLOGY (2002)
Determinants of adherence in adults with cystic fibrosis
LJ Kettler et al.
THORAX (2002)
Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition
MR Kosorok et al.
PEDIATRIC PULMONOLOGY (2001)
Share Paper
